

Application No.: 09/657,336

2

Docket No.: 500862001500

AMENDMENTS TO THE CLAIMS

194.1
193.1
424/108.1
208.1
AGIK
39/385

Claim 1 (Currently amended): An ~~modified~~ anti-viral peptide-albumin conjugate comprising

~~a peptide having been modified to contain an anti-viral peptide comprising a maleimide containing group which is reactive with cysteine 34 of serum albumin to form a stable covalent bond, said peptide comprising and an amino acid sequence wherein said sequence is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:542, SEQ ID NO:543, SEQ ID NO:544, and SEQ ID NO:545, wherein said sequence exhibiting exhibits an anti-viral activity against human immunodeficiency virus (HIV) wherein and said peptide is covalently bonded to cysteine 34 of serum albumin through said maleimide containing group to form said peptide-albumin conjugate, wherein the ratio of peptide to serum albumin in said conjugate is 1:1.~~

Claim 2 (canceled)

Claim 3 (canceled)

2

Claim 4 (Currently amended) The modified anti-viral peptide-albumin conjugate of claim 1 wherein said ~~peptide is DP-107 and comprises the amino acid sequence~~ [[of]]is SEQ ID NO:2.

Claim 5 (canceled)

3

Claim 6 (Currently amended): The modified anti-viral peptide-albumin conjugate of claim 1 wherein said peptide amino acid sequence is selected from the group consisting of SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:542, SEQ ID NO:543, SEQ ID NO:544, and SEQ ID NO:545.

Claims 7-18 (canceled)

sf-2088911

Application No.: 09/657,336

3

Docket No.: 500862001500

⁴
Claim ~~19~~ (Currently amended): A composition for use in the ~~prevention and/or~~ treatment of acquired immune deficiency syndrome (AIDS) comprising, in a physiologically acceptable medium, ~~an modified anti-viral peptide-albumin conjugate including a peptide having been modified to contain a~~ comprising an anti-viral peptide comprising a maleimide containing group and which is reactive with cysteine 34 of serum albumin to form a stable covalent bond, said peptide comprises an amino acid sequence wherein said sequence is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:542, SEQ ID NO:543, SEQ ID NO:544, and SEQ ID NO:545, wherein said sequence exhibiting exhibits an anti-viral activity against human immunodeficiency virus (HIV) wherein and said peptide is covalently bonded to cysteine 34 of serum albumin through said maleimide containing group to form said anti-viral peptide-albumin conjugate, wherein the ratio of peptide to ~~serum albumin in said conjugate~~ is 1:1.

Claim 20 (canceled)

⁵
Claim ~~21~~ (Currently amended): The composition of claim ~~20~~ ⁴ ~~19~~ wherein said peptide is ~~DP 107 comprising the amino acid sequence [[of]]~~ is SEQ ID NO:2.

Claims 22-30 (canceled)

⁶
Claim ~~31~~ (Currently amended): The composition of claim ~~19~~ ⁴ wherein said peptide ~~comprises an amino acid sequence is~~ selected from the group consisting of SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:542, SEQ ID NO:543, SEQ ID NO:544, and SEQ ID NO:545.

Claims 32-35 (canceled)

⁷
Claim ~~36~~ (Currently amended): A composition comprising the ~~modified anti-viral peptide-~~ albumin conjugate of claim 1 in a physiologically acceptable medium.

Claim ~~37~~ (canceled)

sf-2088911

Application No.: 09/657,336

4

Docket No.: 500862001500

8

Claim ~~38~~⁷ (Currently amended): The composition of claim ~~36~~⁷ wherein said ~~modified anti-viral peptide comprises the~~ amino acid sequence ~~[[of]]~~^{is} SEQ ID NO:2.

9

Claim ~~39~~⁷ (Currently amended): The composition of claim ~~36~~⁷ wherein said ~~modified anti-viral peptide comprises an~~ amino acid sequence ~~is~~ selected from the group consisting of SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:542, SEQ ID NO:543, SEQ ID NO:544, and SEQ ID NO:545.

Claim 40-55 (canceled)

Please add the following new claims:

10

Claim ~~56~~¹⁰ (new): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO:147.

11

Claim ~~57~~¹¹ (new): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO:148.

12

Claim ~~58~~¹² (new): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO:149.

13

Claim ~~59~~¹³ (new): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO:179.

14

Claim ~~60~~¹⁴ (new): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO:180.

15

Claim ~~61~~¹⁵ (new): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO:181.

16

Claim ~~62~~¹⁶ (new): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO:542.

sf-2088911

Application No.: 09/657,336

5

Docket No.: 500862001500

¹⁷
Claim ~~63~~ (new): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO:543.

¹⁸
Claim ~~64~~ (new): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO:544.

¹⁹
Claim ~~65~~ (new): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO:545.

²⁰
Claim ~~66~~ (new): The composition of claim ~~19~~⁴ wherein said amino acid sequence is SEQ ID NO:147.

²¹
Claim ~~67~~ (new): The composition of claim ~~19~~⁴ wherein said amino acid sequence is SEQ ID NO:148.

²²
Claim ~~68~~ (new): The composition of claim ~~19~~⁴ wherein said amino acid sequence is SEQ ID NO:149.

²³
Claim ~~69~~ (new): The composition of claim ~~19~~⁴ wherein said amino acid sequence is SEQ ID NO:179.

²⁴
Claim ~~70~~ (new): The composition of claim ~~19~~⁴ wherein said amino acid sequence is SEQ ID NO:180.

²⁵
Claim ~~71~~ (new): The composition of claim ~~19~~⁴ wherein said amino acid sequence is SEQ ID NO:181.

²⁶
Claim ~~72~~ (new): The composition of claim ~~19~~⁴ wherein said amino acid sequence is SEQ ID NO:542.

²⁷
Claim ~~73~~ (new): The composition of claim ~~19~~⁴ wherein said amino acid sequence is SEQ ID NO:543.

sf-2088911

Application No.: 09/657,336

6

Docket No.: 500862001500

²⁸
Claim ~~74~~ (new): The composition of claim ~~18~~⁴ wherein said amino acid sequence is SEQ ID NO:544.

²⁹
Claim ~~75~~ (new): The composition of claim ~~19~~⁴ wherein said amino acid sequence is SEQ ID NO:545.

sf-2088911